riociguat (Adempas)
Jump to navigation
Jump to search
Indications
- FDA-approved to improve exercise capacity in adults with pulmonary hypertension due to
- chronic pulmonary embolism after surgery
- idiopathic pulmonary arterial hypertension
- chronic thromboembolic pulmonary hypertension (CTEPH)
- improves 6 minute walking distance in patients with pulmonary hypertension
Dosage
Adverse effects
- similar to placebo[1]
- diarrhea, dizziness, dyspepsia, headache, nausea, peripheral edema, vomiting[2]
Mechanism of action
- stimulates guanylate cyclase, enhances action of nitric oxide
- diminishes pulmonary artery pressure, increase pulmonary perfusion
More general terms
References
- ↑ 1.0 1.1 Ghofrani H-A et al. Riociguat for the treatment of pulmonary arterial hypertension. N Engl J Med 2013 Jul 25; 369:330 PMID: https://www.ncbi.nlm.nih.gov/pubmed/23883378
Ghofrani H-A et al. Riociguat for the treatment of chronic thromboembolic pulmonary hypertension. N Engl J Med 2013 Jul 25; 369:319. PMID: https://www.ncbi.nlm.nih.gov/pubmed/23883377 - ↑ 2.0 2.1 2.2 FDA News Release: Oct. 8, 2013 FDA approves Adempas to treat pulmonary hypertension http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm370866.htm